Recent upgrades from BofA Securities and KeyBanc have put fresh attention on Schrödinger (SDGR), as the company moves away ...

Schrödinger, Inc. (NASDAQ:SDGR) is one of the best healthcare AI stocks to buy now. On December 15, BofA Securities upgraded ...

Earlier in December 2025, BofA Securities upgraded Schrödinger, Inc. after the company shifted away from internal drug development to concentrate on its core computational software business. This ...

Market conditions remain tough, which is weighing on demand for both Schrödinger's software and drug discovery services. Investors continue to punish Schrödinger's investments in drug discovery, ...

Total Revenue (Q4 2024): $88.3 million, a 19% increase compared to Q4 2023. Software Revenue (Q4 2024): $79.7 million, a 16% increase compared to Q4 2023. Drug Discovery Revenue (Q4 2024): $8.7 ...

Schrodinger reported robust software and drug discovery revenue in the second quarter. Lilly's planned multi-billion-dollar acquisition of Morphic also provides another validation point for ...

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced a research collaboration and license agreement with Novartis to advance multiple development candidates into Novartis’s ...

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today will host its first annual ...

Schrödinger, a little-known software company that helps some of the largest pharmaceutical brands with drug discovery, made its public debut. The company closed its initial public offering on Monday, ...

Schrödinger, which makes software to help design new medicines, said this month that Founded in 1990, the company has U.S. offices in Portland and in New York, where Schrödinger president Ramy Farid ...